{"certainAgreement":{"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"For combination C and D the level of clinical activity observed in Cohorts C11 to C13 and D11 to D32 did not support development beyond Phase 1b. For combination F, the level of clinical activity did not warrant further enrolment. Therefore, Phase 2 was not planned."},"pointOfContact":{"email":"ClinicalTrials.gov_Inquiries@pfizer.com","organization":"Pfizer ClinicalTrials.gov Call Center","phone":"1-800-718-1021","title":"Pfizer Inc."}}